Novel adenovirus vector-based vaccines for HIV-1

Current Opinion in HIV and AIDS

Volumn 5, Issue 5, 2010, Pages 386-390

  Barouch, Dan H ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

adenovirus; HIV 1; vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; CD4 ANTIGEN; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS 1 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; VIRUS RECOMBINANT;

ADENOVIRIDAE; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, SYNTHETIC;

EID: 77955517246     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833cfe4c     Document Type: Review

References (42)

1. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
2. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
3. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
5. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-335.
6. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-372.
7. McElrath MJ, De RosaSC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
8. Buchbinder S. Clinical endpoints in the Step study. In: Proceedings of the Keystone Symposium on HIV Vaccines; Keystone, Colorado, USA; 2009.
9. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15:873-875.
10. Hutnick NA, Carnathan DG, Dubey S, et al. The effects of adenovirus-based HIV-1 vaccines on CD4+ T cells in humans. Nat Med 2009; 15:876-878.
11. Koup RA, Lamoreaux L, Zarkowsky D, et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 2009; 83:6318-6322.
12. D'Souza MP, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010; 24:803-809.
13. Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 2009; 106:1 994019945.
14. Barouch DH. Heterologous rare serotype adenovirus vectors for HIV-1. In: Proceedings of the Keystone Symposium on HIV Vaccines; Banff, Canada; 2010.
15. Sun Y, Bailer RT, Rao SS, et al. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. J Virol 2009; 83:10596-10604.
16. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008; 205:2717-2725.
17. Mullins J. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial. In: Proceedings of the AIDS Vaccine 2009-Scientific Program; Paris, France; 19-22 October 2009.
18. Barouch DH, Kunstman J, Glowczwskie J, et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367-7375.
19. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-339.
20. Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263-8271.
21. Abbink P, Lemckert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654-4663.
22. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting antivector immunity. Nature 2006; 441:239-243.
23. Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001; 75:11603-11613.
24. Fitzgerald JC, GaoGP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003; 170:141 61422.
25. Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of preexisting anti-Ad5 immunity. J Immunol 2004; 172:6290-6297.
26. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132:397-409.
27. Lore K, Adams WC, Havenga MJ, et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 2007; 179:1 721-1 729.
28. Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008; 82:4844-4852.
29. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.
30. Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010; 5:e9015.
31. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005; 79:6516-6522.
32. Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-1533.
33. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547-15555.
34. Barouch DH, Liu J, Lynch DM, et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009; 83:9584-9590.
35. Lemckert AA, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of antiad5 immunity. J Virol 2005; 79:9694-9701.
36. Thorner AR, Lemckert AA, Goudsmit J, et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 2006; 80:12009-12016.
37. Santra S, Sun Y, Korioth-Schmitz B, et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 2009; 27:5837-5845.
38. Casimiro DR, Bett AJ, Fu TM, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004; 78:1143411438.
39. Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100106.
40. Kong WP, Wu L, Wallstrom TC, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009; 83:2201-2215.
41. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-323.
42. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324-328.